Phytosterol Esters Attenuate Hepatic Steatosis in Rats with Non-alcoholic Fatty Liver Disease Rats Fed a High-fat Diet

Overview

Journal Sci Rep

Specialty Science

Date 2017 Feb 8

PMID 28169366

Citations 24

Authors

Lihua Song

Dan Qu

Qing Zhang

Jing Jiang

Haiyue Zhou

Rui Jiang

Yating Li

Yao Zhang

Hongli Yan

Affiliations

Soon will be listed here.

Abstract

Given the adverse effects of drugs used for NAFLD treatment, identifying novel and effective natural compound to prevent NAFLD is urgently needed. In the present study, the effects of phytosterol esters (PSEs) on NAFLD were explored. Adult SD rats were randomized into five groups: normal chow diet (NC), high-fat diet (HF), low-, medium- and high-dose PSE treatment plus high-fat diet groups (PSEL, PSEM, and PSEH). Our results showed that the levels of LDL-C in the PSEL group and hepatic TG, TC, and FFA in the three PSEs groups were significantly decreased. Notably, the uric acid (UA) level was significantly decreased by PSEs intervention. The hepatic inflammatory stress was ameliorated via the inhibition of the cytokines, including TGF-β, IL-6, IL-10 and CRP in the PSEs intervention groups. Further, the oxidative status was improved by PSE treatment through adjusting the enzyme activity (SOD and XOD) and decreasing the MDA level. These beneficial effects of PSE may have been partly due to its regulation on the expression of TGF-β1, TGF-β2, TNF-α, UCP-2, PPAR-α and PPAR-γ in hepatic tissue at both mRNA and protein level. The results of this study suggest that PSEs may be used as therapeutic agents for the prevention and progression of NAFLD and that hyperuricemia is induced by high-fat diet consumption.

Citing Articles

Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model.

Gillet R, Cerda-Drago T, Branes M, Valenzuela R Int J Mol Sci. 2025; 26(2).

PMID: 39859279 PMC: 11766071. DOI: 10.3390/ijms26020564.

Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.

Svobodova G, Horni M, Velecka E, Bousova I Arch Toxicol. 2024; 99(1):1-22.

PMID: 39443317 PMC: 11748479. DOI: 10.1007/s00204-024-03889-x.

Effects of Chronic Sleep Restriction on Transcriptional Sirtuin 1 Signaling Regulation in Male Mice White Adipose Tissue.

Rendine M, Cocci P, de Vivo L, Bellesi M, Palermo F Curr Issues Mol Biol. 2024; 46(3):2144-2154.

PMID: 38534754 PMC: 10969409. DOI: 10.3390/cimb46030138.

Unsaponifiable Matter from Wheat Bran Cultivated in Korea Inhibits Hepatic Lipogenesis by Activating AMPK Pathway.

An M, Heo H, Park J, Jeong H, Kim Y, Lee J Foods. 2023; 12(21).

PMID: 37959135 PMC: 10650137. DOI: 10.3390/foods12214016.

β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway.

Abo-Zaid O, Moawed F, Ismail E, Farrag M BMC Pharmacol Toxicol. 2023; 24(1):31.

PMID: 37173727 PMC: 10182633. DOI: 10.1186/s40360-023-00671-0.

References

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Gressner A, Weiskirchen R, Breitkopf K, Dooley S . Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002; 7:d793-807. DOI: 10.2741/A812. View

Angulo P, Keach J, Batts K, Lindor K . Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-62. DOI: 10.1002/hep.510300604. View

Provenzano A, Milani S, Vizzutti F, Delogu W, Navari N, Novo E . n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. Liver Int. 2014; 34(6):918-30. DOI: 10.1111/liv.12500. View

Saggiani F, Pilati S, Targher G, Branzi P, Muggeo M, Bonora E . Serum uric acid and related factors in 500 hospitalized subjects. Metabolism. 1996; 45(12):1557-61. DOI: 10.1016/s0026-0495(96)90188-2. View

Shih M, Lazo M, Liu S, Bonekamp S, Hernaez R, Clark J . Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015; 114(4):314-20. PMC: 6312686. DOI: 10.1016/j.jfma.2012.11.014. View

Cordeiro A, Pereira S, Saboya C, Ramalho A . Nonalcoholic Fatty Liver Disease Relationship with Metabolic Syndrome in Class III Obesity Individuals. Biomed Res Int. 2015; 2015:839253. PMC: 4450272. DOI: 10.1155/2015/839253. View

Esterbauer H, Schaur R, Zollner H . Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991; 11(1):81-128. DOI: 10.1016/0891-5849(91)90192-6. View

Nakatsu Y, Seno Y, Kushiyama A, Sakoda H, Fujishiro M, Katasako A . The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015; 309(1):G42-51. DOI: 10.1152/ajpgi.00443.2014. View

10.

Xiao X, Wiersch J, El-Gohary Y, Guo P, Prasadan K, Paredes J . TGFβ receptor signaling is essential for inflammation-induced but not β-cell workload-induced β-cell proliferation. Diabetes. 2012; 62(4):1217-26. PMC: 3609557. DOI: 10.2337/db12-1428. View

11.

Zaitone S, Barakat B, Bilasy S, Fawzy M, Abdelaziz E, Farag N . Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388(6):587-600. DOI: 10.1007/s00210-015-1102-9. View

12.

Gerin I, Dolinsky V, Shackman J, Kennedy R, Chiang S, Burant C . LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem. 2005; 280(24):23024-31. DOI: 10.1074/jbc.M412564200. View

13.

Chitturi S, Farrell G . Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21(1):27-41. DOI: 10.1055/s-2001-12927. View

14.

Ahn S, Jang K, Won Jun D, Lee B, Shin K . Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59(12):2975-82. DOI: 10.1007/s10620-014-3289-x. View

15.

Gupta R, Sharma A, Dobhal M, Sharma M, Gupta R . Antidiabetic and antioxidant potential of β-sitosterol in streptozotocin-induced experimental hyperglycemia. J Diabetes. 2010; 3(1):29-37. DOI: 10.1111/j.1753-0407.2010.00107.x. View

16.

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

17.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

18.

Cai W, Song J, Zhang B, Sun Y, Yao H, Zhang Y . The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population. ScientificWorldJournal. 2014; 2014:393628. PMC: 3910275. DOI: 10.1155/2014/393628. View

19.

Ahmed M, Byrne C . Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes Obes Metab. 2010; 12(11):958-66. DOI: 10.1111/j.1463-1326.2010.01261.x. View

20.

Gylling H, Plat J, Turley S, Ginsberg H, Ellegard L, Jessup W . Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014; 232(2):346-60. DOI: 10.1016/j.atherosclerosis.2013.11.043. View